Abstract:Introduction: Japanese encephalitis virus (JEV) and Zika virus (ZIKV) pose a severe threat to human health. Our previous research results, as well as those of other research groups, indicated that antibodies (Abs) induced by JEV infection or JEV vaccine vaccination could enhance ZIKV infection in vitro and exacerbate the mortality of ZIKV-infected mice, vice versa, which is known as antibody-dependent enhancement (ADE). Although studies on other flaviviruses revealed that altering the amino acid residues located in the fusion loop (FL) of envelope (E) protein can reduce the level of flavivirus-cross-reactive Abs, thereby abating the ADE of heterologous flavivirus infection, it is unclear whether this strategy is equally applicable to JEV. Methods: In this study, we constructed recombinant adenoviruses and nucleotide-modified mRNA-lipid nanoparticle (LNP) encoding JEV wild-type E protein or E protein mutant (designated as Ad5-JEV-E WT and Ad5-JEV-E mut ; JEV-E WT mRNA-LNP, and JEV-E mut mRNA-LNP). We evaluated the immunogenicity of these vaccine candidates in mice and the capacity of vaccine-immune mouse sera to neutralize JEV infection or mediate ADE of ZIKV infection in vitro and in vivo . Results: Ad5-JEV-E mut or JEV-E mut mRNA-LNP immunization induced ZIKV-cross-reactive Ab response which is dramatically lower than that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The levels of JEV-neutralizing Abs induced by Ad5-JEV-E mut or JEV-E mut mRNA-LNP are comparable to that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The ability of Abs induced by Ad5-JEV-E mut to enhance ZIKV infection in vitro is attenuated as compared with that induced by Ad5-JEV-E WT . Moreover, JEV-E mut mRNA-LNP immunization elicited potent T cell response similar to JEV-E WT mRNA-LNP in mice. Mice immunized with each mRNA-LNP exhibited lower level of serum viral load than the mock-immunized mice post JEV challenge. Mice receiving JEV-E WT mRNA-LNP-immune mouse sera exhibited ADE post ZIKV challenge whereas passively transferred JEV-E mut mRNA-LNP-immune mouse sera did not lead to obvious ADE of ZIKV infection in recipient mice. Most importantly, maternally acquired Abs did not enhance the mortality of 1-day-old neonates born to JEV-E mut mRNA-LNP-immunized mice post ZIKV challenge. Discussion: These results suggest that optimizing the FL sequence of JEV could significantly reduce the level of JEV/ZIKV-cross-reactive Abs and abrogate the ADE of ZIKV infection, providing a promising strategy to develop effective and safety JEV vaccine.

Virulence and Cross-Protection Conferred by an Attenuated Genotype I-Based Chimeric Japanese Encephalitis Virus Strain Harboring the E Protein of Genotype V in Mice

Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus

Mutation of Putative N-linked Glycosylation Sites in Japanese Encephalitis Virus Premembrane and Envelope Proteins Enhances Humoral Immunity in BALB/C Mice after DNA Vaccination.

Investigation of Immune Response Induction by Japanese Encephalitis Live‐attenuated and Chimeric Vaccines in Mice

Complete protection for mice conferred by a DNA vaccine based on the Japanese encephalitis virus P3 strain used to prepare the inactivated vaccine in China

A Molecularly Cloned, Live-Attenuated Japanese Encephalitis Vaccine SA14-14-2 Virus: a Conserved Single Amino Acid in the Ij Hairpin of the Viral E Glycoprotein Determines Neurovirulence in Mice.

Genomic Characteristics and E Protein Bioinformatics Analysis of JEV Isolates from South China from 2011 to 2018

[Japanese Encephalitis Virus with Genotype I is Predominant in Sichuan Province].

Increased Cleavage of Japanese Encephalitis Virus prM Protein Promotes Viral Replication but Attenuates Virulence

The Safety and Immunity at a Recombinant Pseudorabies Virus Expression NS_(1) Protein of Japanese Encephalitic Virus

Japanese encephalitis virus E protein domain III immunization mediates cross-protection against Zika virus in mice via antibodies and CD8 + T cells

The mutation of Japanese encephalitis virus envelope protein residue 389 attenuates viral neuroinvasiveness

Molecular Detection and Genetic Characterization of Japanese Encephalitis Virus in Animals from 11 Provinces in China

An enterovirus A71 virus-like particle with replaced loops confers partial cross-protection in mice

Chimeric enterovirus 71 virus-like particle displaying conserved coxsackievirus A16 epitopes elicits potent immune responses and protects mice against lethal EV71 and CA16 infection

An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice

The pre membrane and envelope protein is the crucial virulence determinant of Japanese encephalitis virus

Epitope(s) involving amino acids of the fusion loop of Japanese encephalitis virus envelope protein is(are) important to elicit protective immunity

Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidate

Insights into the Pathogenesis and Development of Recombinant Japanese Encephalitis Virus Genotype 3 as a Vaccine

Evaluation of Environment Safety of a Japanese Encephalitis Live Attenuated Vaccine.